June 26 (Reuters) - Neurobo Pharmaceuticals Inc
:
* NEUROBO PHARMACEUTICALS DOSES FIRST PATIENT IN THE MAD PART 2 OF ITS PHASE 1 CLINICAL TRIAL EVALUATING DA-1726 FOR THE TREATMENT OF OBESITY
* NEUROBO PHARMACEUTICALS: TOP-LINE DATA READOUT FROM SINGLE ASCENDING DOSE PART 1 EXPECTED IN Q3 2024 & FROM MULTIPLE ASCENDING DOSE PART 2 IN Q1 2025
* NEUROBO PHARMACEUTICALS INC: PLANNED PART 3 INTERIM DATA READOUT EXPECTED MID-2026 WITH TOP-LINE DATA IN SECOND HALF OF 2026
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.